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The Promise of Myocardial Fibrosis Assessment
by T1 Mapping*
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pTwo intertwined needs have promoted the devel-
opment of T1 mapping in cardiac magnetic reso-
nance (CMR) during the past decade. The first
need relates to the desire for greater spatial granu-
larity as investigators venture outside the infarct-
and scar-sizing paradigm to probe the regional
heterogeneity of myocardial damage associated with
diverse disease processes (1–3), the substrate of
arrhythmias (4,5), and the possibility of CMR-
guided arrhythmia ablation (6), as well as stem cell
therapy (7). The second need, also rooted in the
desire to investigate tissue structure using CMR,
results in large part from the dependence on con-
trast kinetics that imposes significant limitations to
a more complete understanding of basic cardiac
disease processes (8,9). In this issue of iJACC, the
report by Puntmann et al. (10) gets us closer to both
goals by demonstrating that T1 mapping, carefully
performed at 3-T, not only advances our knowledge
of differences in the size and/or type of myocardial
extracellular space associated with different diseases,
but perhaps allows us to perform such assessment
without or before contrast administration.
See page 475
The investigators compared measures of T1
mapping obtained from 25 patients with known
asymmetric hypertrophic cardiomyopathy and from
27 patients with known dilated nonischemic car-
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to disclose.iomyopathy with a group of 30 normotensive
ontrols of similar age and sex distribution and with
ow pre-test probability of developing left ventric-
lar cardiomyopathy. They measured T1 in the
nterventricular septum before and at 10, 20, and 30
in after contrast administration using an estab-
ished steady-state free precession Look-Locker
maging pulse sequence at 3-T, with motion cor-
ection during data processing. They found differ-
nces in pre-contrast and post-contrast T1 times up
o 30 min after gadolinium administration between
ontrols and patients with cardiomyopathy, whereas
o differences were found between the 2 groups of
atients with hypertrophic and dilated nonischemic
ardiomyopathies. Moreover, when pre-contrast
nd 20-min post-contrast measures were integrated
nd represented in relation to parallel measures in
lood, the derived extracellular volume (ECV) in-
exes obtained from patients with hypertrophic
0.31  0.10) and nonischemic dilated (0.30 
.05) cardiomyopathy were greater than those ob-
ained from patients in the control group (0.20 
.06). Similar relationships were found for ECVs at
0 and 30 min after contrast administration, as well
s for the partition coefficients calculated before
djustment for blood cell intravascular volume at
ach of the post-contrast times. The investigators
onclude that T1 mapping allows the differentiation
f myocardial tissue characteristics between patients
ith cardiomyopathies compared with normoten-
ive controls of similar age and sex distributions.
oreover, they highlight the fact that differences
etween patients with cardiomyopathy and controls
ould be detected from T1 values obtained before
ontrast administration, underscoring the method’s
ower to elicit different tissue signatures in the
bsence of a selective extracellular indicator.
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486The latter finding has implications beyond its
potential use to differentiate patients with myo-
pathic processes from those without such processes.
Does it mean that extracellular matrix alterations
can be quantified by T1 mapping even when diluted
by the presence of larger intracellular spaces pre-
sumed similar between cardiomyopathy patients
and controls? Or does it mean that they parallel
intracellular alterations, leading to a greater magni-
tude of pre-contrast T1 signal detectable at 3-T by
the methods used in this work? If so, what kind of
alterations would those be, and what kind of myo-
cardial pathological processes would they reflect
beyond the substitution of myocytes for fibroblasts
and corresponding increase in collagen deposition
that accompany the well-described extracellular
matrix alterations associated with cardiomyopathy?
The findings do suggest that the primary changes
are extracellular, given the accompanying differ-
ences in post-contrast times and ECV values and
that they are of such magnitude in patients with
cardiomyopathy that they can be detected by T1
mapping at 3-T before contrast administration.
However, as the power of CMR technology in-
creases, mitochondrial structural abnormalities
and/or other potential intracellular alterations asso-
ciated with myocardial disease processes should be
kept in mind as potential contributing mechanisms
for differences detected before contrast administra-
tion. In the meantime, the very possibility of dif-
ferentiating between normal and diseased myocar-
dium for purely diagnostic purposes should not be
underestimated given the limitations of administer-
ing gadolinium-based substances to patients, par-
ticularly those with renal dysfunction.
The study results should of course be interpreted
in light of its potential limitations, in large part
discussed by the investigators. When comparing
groups of patients with known disease against
nondiseased controls, differences tend to be magni-
fied, whereas borderline situations and milder dis-
ease presentations tend to be reduced, potentially
resulting in overestimation of the ultimate diagnos-
tic method’s power. Prospective studies using in-
tention to diagnose will ultimately demonstrate the
diagnostic power of T1 measures to distinguish
patients with cardiomyopathy from those without
disease within a pool of patients with suspected
disease. Moreover, the choice of sampling from thetechnical considerations highlighted in previous
studies (11,12), may have magnified differences
between patients with asymmetric hypertrophic
cardiomyopathy and controls, while potentially re-
ducing differences between the latter and those with
dilated cardiomyopathy. Myocardial fibrosis altera-
tions are known to be more pronounced in the
septum as opposed to other left ventricular wall
segments in patients with asymmetric hypertrophic
cardiomyopathy. The latter theoretical concern
does not diminish the validity of the diagnostic
findings reported, but should be kept in mind when
patients with other types of hypertrophic cardiomy-
opathy are being considered for diagnostic T1
mapping.
The investigators should be congratulated for the
performance of such sophisticated studies at high
field strength, including the careful reproducibility
of post-contrast times and the methods customized
for motion correction used for data analysis. In
addition to the practical applicability of the main
results, the study has many implications beyond the
detected pre-contrast differences and the potential
extracellular versus intracellular abnormalities they
may reflect. The fact that no differences in the
ECVs (or T1 times) of patients with hypertrophic
versus dilated nonischemic cardiomyopathies were
found is thought provoking in many ways. Does it
mean that the extracellular matrix is altered in a
similar manner in both processes? Does the absence
of differences reflect advanced septal disease in both
processes? Do the measured indexes of ECV en-
largement reflect true ECV size augmentation, a
change in the relaxivity of water associated with
collagen in the extracellular space, or both? The
investigators discuss the potential influence of pro-
cesses that could alter T2 relaxation times as well as
several other potential implications of this work.
The future and potential of CMR T1 mapping is
certainly enhanced by this study. Hopefully, pa-
tients with suspected cardiomyopathy will be de-
tected and treated earlier as a result of this investi-
gation and other similar efforts in this field.
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